Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|August 31, 2020
FDA Expands EUA for Remdesivir
Under expanded FDA authorization, Gilead Sciences’ antiviral treatment for COVID-19 can be administered to all hospitalized patients.
Advertisement
On Aug. 28, 2020, FDA expanded the emergency use authorization (EUA) for Gilead Sciences’ investigational antiviral drug Veklury (remdesivir) to allow treatment of all hospitalized patients with COVID-19; the initial EUA issued on May 1 applied to patients hospitalized with low blood oxygen levels or those needing oxygen therapy or more intensive breathing support such as a ventilator.
The expanded EUA is based on results from a Phase III trial evaluating Veklury in hospitalized patients with moderate COVID-19 pneumonia, and a National Institute of Allergy and Infectious Diseases trial in hospitalized patients with a range of disease severity.
“As our understanding of the spectrum of SARS-CoV-2 infection and the presentations and severity of COVID-19 continues to evolve, these results and the expanded EUA represent a new, important step that streamlines bedside prescribing of remdesivir without having to wait for patients to worsen clinically,” said Francisco Marty, MD, an infectious diseases physician at Brigham and Women’s Hospital and associate professor of medicine at Harvard Medical School, in a Gilead Sciences press release. “These study results show that patients with moderate COVID-19 disease may also benefit from a five-day treatment course of remdesivir.”
In a statement, FDA noted, “based on the Agency’s ongoing review of the EUA, including its review of the totality of scientific information now available, the FDA has determined that it is reasonable to believe Veklury may be effective for the treatment of suspected or laboratory-confirmed COVID-19 in all hospitalized adult and pediatric patients. The Agency’s review has also concluded that the known and potential benefits of Veklury outweigh the known and potential risks for these uses.”
Sources:
Advertisement
Related to this article
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
The FDA has approved remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement